New combo aims to keep leukemia in check after remission
NCT ID NCT07539818
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding venetoclax to azacitidine as maintenance therapy helps adults with acute myeloid leukemia (AML) stay in remission longer. About 788 patients who achieved first remission after initial treatment will receive either azacitidine alone or azacitidine plus venetoclax for up to 12 cycles. The main goal is to see if the combination improves disease-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- azacitidine and venetoclax
- What this could lead to
- If successful, this could offer a more effective maintenance therapy to keep AML in remission longer, potentially reducing relapse risk.
- What could go wrong
- This is an early-stage Phase 3 trial with no results yet. The combination may cause more side effects, and it's unclear if it will improve survival or just delay relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tailored chemo cocktail outsmart a common leukemia?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can pressurized oxygen boost cord blood transplants?
- Personalized leukemia vaccine aims to outsmart relapse
- Supercharged donor cells aim to stop leukemia return after transplant